Real‐world use and outcomes of dolutegravir‐containing antiretroviral therapy in HIV and tuberculosis co‐infection: a site survey and cohort study in sub‐Saharan Africa

INTRODUCTION: Dolutegravir is being scaled up globally as part of antiretroviral therapy (ART), but for people with HIV and tuberculosis co‐infection, its use is complicated by a drug–drug interaction with rifampicin requiring an additional daily dose of dolutegravir. This represents a disadvantage...

Descripción completa

Detalles Bibliográficos
Autores principales: Romo, Matthew L., Brazier, Ellen, Mahambou‐Nsondé, Dominique, De Waal, Reneé, Sekaggya‐Wiltshire, Christine, Chimbetete, Cleophas, Muyindike, Winnie R., Murenzi, Gad, Kunzekwenyika, Cordelia, Tiendrebeogo, Thierry, Muhairwe, Josephine A., Lelo, Patricia, Dzudie, Anastase, Twizere, Christelle, Rafael, Idiovino, Ezechi, Oliver C., Diero, Lameck, Yotebieng, Marcel, Fenner, Lukas, Wools‐Kaloustian, Kara K., Shah, N. Sarita, Nash, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289708/
https://www.ncbi.nlm.nih.gov/pubmed/35848120
http://dx.doi.org/10.1002/jia2.25961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289708/
https://www.ncbi.nlm.nih.gov/pubmed/35848120
http://dx.doi.org/10.1002/jia2.25961

Ejemplares similares